TLSI (TriSalus Life Sciences) Total Inventories: $4.21 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TLSI TriSalus Life Sciences Inc TLSI
26 GF Score
Price $5.27
GF Value $3.77
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is TriSalus Life Sciences Total Inventories?

TriSalus Life Sciences TLSI +0.57% 26 Total Inventories is $4.21 Mil as of Jun. 2026. GuruFocus rates TLSI with a GF Score™ of 26/100 and a GF Value™ of $3.77 (Significantly Overvalued). The stock has 6 warning signs investors should review.

TriSalus Life Sciences's total inventories for the quarter that ended in Jun. 2026 was $4.21 Mil. TriSalus Life Sciences's average total inventories from the quarter that ended in Mar. 2026 to the quarter that ended in Jun. 2026 was $3.99 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. TriSalus Life Sciences's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was $-0.04.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. TriSalus Life Sciences's Days Inventory for the three months ended in Jun. 2026 was 241.53.

Inventory Turnover measures how fast the company turns over its inventory within a year. TriSalus Life Sciences's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.38.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. TriSalus Life Sciences's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.35.


TriSalus Life Sciences  (NAS:TLSI) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

TriSalus Life Sciences's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is

Net-Net Working Capital Per Share (Q: Jun. 2026 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(46.288+0.75 * 6.459+0.5 * 4.205-55.898
-0-0)/61.470
=-0.04

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

TriSalus Life Sciences's Days Inventory for the three months ended in Jun. 2026 is calculated as:

Days Inventory=Average Total Inventories (Q: Jun. 2026 )/Cost of Goods Sold (Q: Jun. 2026 )*Days in Period
=3.9915/1.508*365 / 4
=241.53

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

TriSalus Life Sciences's Inventory Turnover for the quarter that ended in Jun. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Jun. 2026 ) / Average Total Inventories (Q: Jun. 2026 )
=1.508 / 3.9915
=0.38

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

TriSalus Life Sciences's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Jun. 2026 ) / Revenue (Q: Jun. 2026 )
=3.9915 / 11.407
=0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


TriSalus Life Sciences Total Inventories Related Terms


TriSalus Life Sciences Total Inventories Historical Data

* Premium members only.

The historical data trend for TriSalus Life Sciences's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TriSalus Life Sciences Total Inventories Chart

TriSalus Life Sciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Inventories
1.29 1.47 2.55 4.05 3.08

TriSalus Life Sciences Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.81 3.28 3.08 3.78 4.21
TLSI
26GF Score
TriSalus Life Sciences Inc TLSI
Total Inventories is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TriSalus Life Sciences Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of $4.21 Mil mean?
TriSalus Life Sciences (TLSI) has a Total Inventories of $4.21 Mil as of Jun. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for TriSalus Life Sciences and its competitors.
Is TriSalus Life Sciences' Total Inventories too high?
TriSalus Life Sciences' current Total Inventories is $4.21 Mil. Overall, TriSalus Life Sciences has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TriSalus Life Sciences' Total Inventories compare to TMCI and SENS?
TriSalus Life Sciences' Total Inventories of $4.21 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Devices & Instruments company?
A good Total Inventories depends on the Medical Devices & Instruments industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for TriSalus Life Sciences and its competitors. TriSalus Life Sciences's current Total Inventories is $4.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TriSalus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, TriSalus Life Sciences (TLSI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.77, compared to a current price of $5.27 — trading 39.8% above its estimated fair value. The current Total Inventories is $4.21 Mil. TriSalus Life Sciences' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For TriSalus Life Sciences (TLSI), the current Total Inventories is $4.21 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TriSalus Life Sciences (TLSI) Overvalued in 2026?

Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be overvalued. The current stock price of $5.27 is trading 39.8% above its estimated GF Value™ of $3.77. GuruFocus considers TriSalus Life Sciences to be Significantly Overvalued.

Key valuation signals for TLSI:

  • Total Inventories: $4.21 Mil
  • GF Value™: $3.77 vs. price of $5.27 (39.8% above fair value)
  • GF Score™: 26/100 with 6 warning signs

No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TriSalus Life Sciences Business Description

Address 6272 W. 91st Avenue, Westminster, CO, USA, 80031
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
26GF Score

Get the complete analysis for TLSI

Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.27
Price
$3.77
GF Value